Recent studies have underscored the potential role of CEA in predicting treatment response, overall survival, and metastatic disease in pancreatic cancer.3–5 Our findings support this evolving perspective and offer a more nuanced, biomarker-driven approach to BR-PDAC management. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.